Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element - PubMed (original) (raw)

Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element

F Wang et al. J Virol. 1991 Aug.

Abstract

Epstein-Barr virus (EBV) nuclear protein 2 (EBNA-2) is essential for B-lymphocyte growth transformation. EBNA-2 upregulates mRNAs encoding CD23, a B-lymphocyte surface protein closely associated with EBV-induced growth transformation. To further investigate this EBNA-2 effect, we searched in the genomic DNA spanning the type a and type b CD23 mRNA start sites for a cis-acting fragment that would render a promoter transactivatable by EBNA-2. An 800-bp CD23 DNA fragment (-335 to +465 relative to the type a CD23 mRNA start site) conferred EBNA-2 responsiveness to the herpes simplex virus thymidine kinase (TK) promoter when transfected into EBV-negative B-lymphoma cells. Deletional analysis identified a -275/-89 subfragment that was EBNA-2 responsive when cloned in either orientation and at variable distances upstream of the heterologous promoter. EBNA-2 and the cis-acting CD23 element increased TK-promoted mRNA and did not alter the herpes simplex virus TK promoter transcription start site. As expected, a type a CD23 promoter (-335/+80) which contained the EBNA-2-responsive element was transactivated by EBNA-2. As in EBV infection and stable EBNA-2 transfection, the CD23 DNA element in cis with heterologous or homologous promoters was less responsive to type 2 than to type 1 EBNA-2, whereas the EBNA-2-responsive DNA fragment from the EBV latent membrane protein 1 promoter was more responsive to the type 2 EBNA-2. These experiments delineate a 186-bp, EBNA-2-responsive cell DNA fragment and provide firm evidence that EBNA-2 transactivates transcription of cell genes. The greater type 1 versus type 2 EBNA-2 responsiveness of the CD23 promoter and the lack of a similar effect on the latent membrane protein 1 promoter is consistent with the hypothesis that greater cell gene transactivation by type 1 EBNA-2 is the basis for the more efficient growth-transforming properties of type 1 EBV.

PubMed Disclaimer

Similar articles

• Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
  Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E. Wang F, et al. J Virol. 1990 May;64(5):2309-18. doi: 10.1128/JVI.64.5.2309-2318.1990. J Virol. 1990. PMID: 2157887 Free PMC article.
• Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression.
  Tsang SF, Wang F, Izumi KM, Kieff E. Tsang SF, et al. J Virol. 1991 Dec;65(12):6765-71. doi: 10.1128/JVI.65.12.6765-6771.1991. J Virol. 1991. PMID: 1658373 Free PMC article.
• EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
  Ling PD, Hsieh JJ, Ruf IK, Rawlins DR, Hayward SD. Ling PD, et al. J Virol. 1994 Sep;68(9):5375-83. doi: 10.1128/JVI.68.9.5375-5383.1994. J Virol. 1994. PMID: 8057421 Free PMC article.
• Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation.
  Cohen JI, Wang F, Kieff E. Cohen JI, et al. J Virol. 1991 May;65(5):2545-54. doi: 10.1128/JVI.65.5.2545-2554.1991. J Virol. 1991. PMID: 1850028 Free PMC article.
• Immortalizing genes of Epstein-Barr virus.
  Middleton T, Gahn TA, Martin JM, Sugden B. Middleton T, et al. Adv Virus Res. 1991;40:19-55. doi: 10.1016/s0065-3527(08)60276-6. Adv Virus Res. 1991. PMID: 1659776 Review.

Cited by

• Carcinogenic mechanisms of virus-associated lymphoma.
  Zhang Y, Guo W, Zhan Z, Bai O. Zhang Y, et al. Front Immunol. 2024 Feb 28;15:1361009. doi: 10.3389/fimmu.2024.1361009. eCollection 2024. Front Immunol. 2024. PMID: 38482011 Free PMC article. Review.
• Cancers associated with human gammaherpesviruses.
  Wen KW, Wang L, Menke JR, Damania B. Wen KW, et al. FEBS J. 2022 Dec;289(24):7631-7669. doi: 10.1111/febs.16206. Epub 2021 Oct 2. FEBS J. 2022. PMID: 34536980 Free PMC article. Review.
• Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
  Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J, Etna MP, Rieger S, Kempkes B, Coccia EM, Sui SJH, Chen CS, Uccini S, Avigan D, Faggioni A, Trivedi P, Slack FJ. Anastasiadou E, et al. Leukemia. 2019 Jan;33(1):132-147. doi: 10.1038/s41375-018-0178-x. Epub 2018 Jun 26. Leukemia. 2019. PMID: 29946193 Free PMC article.
• Characterization of the EBV-Induced Persistent DNA Damage Response.
  Hafez AY, Luftig MA. Hafez AY, et al. Viruses. 2017 Dec 1;9(12):366. doi: 10.3390/v9120366. Viruses. 2017. PMID: 29194355 Free PMC article.
• Limited nucleotide pools restrict Epstein-Barr virus-mediated B-cell immortalization.
  Hafez AY, Messinger JE, McFadden K, Fenyofalvi G, Shepard CN, Lenzi GM, Kim B, Luftig MA. Hafez AY, et al. Oncogenesis. 2017 Jun 12;6(6):e349. doi: 10.1038/oncsis.2017.46. Oncogenesis. 2017. PMID: 28604764 Free PMC article.

References

1. 1. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7390-4 - PubMed
2. 1. J Exp Med. 1986 Nov 1;164(5):1455-69 - PubMed
3. 1. J Virol. 1991 May;65(5):2164-9 - PubMed
4. 1. Science. 1991 Jan 4;251(4989):70-2 - PubMed
5. 1. J Immunol. 1989 Nov 1;143(9):3087-92 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program